EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multibinding inhibitors of HMG-CoA reductase



Multibinding inhibitors of HMG-CoA reductase



Official Gazette of the United States Patent & Trademark Office Patents 1256(2), Mar 12



Disclosed are multibinding compounds which inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-COA reductase), the rate limiting enzyme in cholesterol biosynthesis. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is a moiety capable of binding to HMG-CoA reductase and the distance between ligands is at least 10 ANG. The multibinding compounds of this invention are useful in the treatment and prevention of hypercholesterolemia, hyperlipidemia, atherosclerosis and the like.

(PDF 0-2 workdays service: $29.90)

Accession: 035349695

Download citation: RISBibTeXText



Related references

Multibinding inhibitors of cyclooxygenase-2. Official Gazette of the United States Patent & Trademark Office Patents 1258(4), May 28, 2002

Multibinding inhibitors of microsomal triglyceride transferase protein. Official Gazette of the United States Patent & Trademark Office Patents 1250(2), Sep 11, 2001

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88(1-2): 1-9, 2012

Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Pharmacological Reports 67(1): 44-51, 2016

Similarities and differences in the inhibition of rat lens aldose reductase and kidney aldehyde reductase by aldose reductase inhibitors. Investigative Ophthalmology & Visual Science 30(3 SUPPL): 193, 1989

Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. American Journal of Cardiology 91(12A): 12H-18H, June 19, 2003

Pharmacokinetic interaction between propranolol and the hmg coenzyme a reductase a reductase inhibitors pravastatin and lovastatin. British Journal of Clinical Pharmacology 31(6): 665-670, 1991

Charge is the major discriminating factor for glutathione reductase versus trypanothione reductase inhibitors. Bioorganic & Medicinal Chemistry 4(8): 1247-1253, 1996

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Journal of Atherosclerosis and Thrombosis 7(3): 138-144, 2001

The effect of flavins and enzyme inhibitors on 4-nitrobenzoic acid reductase and azo reductase of Ascaris lumbricoides var suum. Xenobiotica; the Fate of Foreign Compounds in Biological Systems 5(11): 657-663, 1975

Platinum complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. Journal of Medicinal Chemistry 43(25): 4812-4821, December 14, 2000

Exploring functional roles of multibinding protein interfaces. Protein Science 18(8): 1674-1683, 2009

(2,2':6',2"-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase. Journal of Medicinal Chemistry 43(25): 4812-4821, 2000

Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorganic & Medicinal Chemistry 17(3): 1244-1250, 2009